Detalhe da pesquisa
1.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Lancet
; 389(10068): 519-527, 2017 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28017406
2.
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 15(2): 230-269, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188192
3.
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
J Natl Compr Canc Netw
; 14(4): 389-400, 2016 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27059188
4.
Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent.
Bioorg Med Chem Lett
; 26(4): 1272-5, 2016 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26774653
5.
Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.
J Immunol
; 190(6): 2966-75, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23408834
6.
Daratumumab proves safe and highly effective in AL amyloidosis.
Br J Haematol
; 185(2): 342-344, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938774
7.
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
Blood
; 120(14): 2817-25, 2012 Oct 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-22833546
8.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-22555973
9.
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Am J Hematol
; 89(4): 349-54, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24273135
10.
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Clin Lymphoma Myeloma Leuk
; 22(8): e770-e776, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35504808
11.
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
Cancers (Basel)
; 13(11)2021 May 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34071205
12.
DNA methylation inhibition in myeloma: Experience from a phase 1b study of low-dose continuous azacitidine in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Semin Hematol
; 58(1): 45-55, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33509443
13.
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Blood Cancer J
; 10(5): 53, 2020 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32393732
14.
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Cancer Res
; 66(5): 2785-93, 2006 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16510600
15.
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Leukemia
; 32(10): 2250-2262, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29632340
16.
Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Ann Hematol
; 86(10): 711-7, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17622529
17.
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis.
PLoS One
; 12(3): e0172996, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28278302
18.
Type 1 cryoglobulinemia: response to thalidomide and lenalidomide.
J Clin Rheumatol
; 17(3): 145-7, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21441816
19.
Phase I Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Patients with Previously Treated Multiple Myeloma.
Oncol Ther
; 4(2): 287-301, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-28261656
20.
Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.
J Hematol Oncol
; 9(1): 125, 2016 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27855695